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ng author.Summary Adding long-acting beta agonists (LABA) to inhaled corticosteroids (ICS)
has been associated with beneficial effects in COPD patients in randomized
controlled trials and observational studies. However, it is not known whether adding
short-acting beta agonists (SABA) to ICS instead of LABA will be similarly effective in
COPD. We compared the effectiveness of combination therapies involving ICS with
LABA versus ICS with SABA in reducing risk of re-hospitalization or death among COPD
patients within a year of discharge from a first COPD hospitalization. Using the UK
General Practice Research Database, we obtained 437 pairs of patients who either
used ICS plus LABA or ICS plus SABA, each pair having been matched on disease
severity. We found that 12.1% of patients prescribed ICS with LABA experienced re-
hospitalization or death within 12 months compared with 18.1% among those given
ICS with SABA. In multivariate analyses, we found a 38% risk reduction (Po0:007)
among patients given ICS with LABA relative to those given ICS with SABA. Models
stratified by SABA use generated a risk reduction of 35% (P ¼ 0:02) among those given
ICS and LABA with SABA in the 90-day period, and of 49% (Po0:05) among those given
ICS and LABA without any SABA compared with the combination users of ICS and
SABA. We conclude that in moderate to severe COPD patients, the combined use of
ICS with LABA is more effective in reducing the risk of re-hospitalization or death
than the combined use of ICS with SABA.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is a
multi-component respiratory disorder character-
ized by deterioration in lung function in the form of
negative changes to expiratory flow. COPD is one of
the fastest growing diseases in the world, and
although it is currently only the sixth leading cause
of death with more than 2.5 million deaths per year
worldwide, it is the only major disease with an
increasing annual trend of mortality.1 Indeed, COPD
is estimated to be the third most important cause
of death by 2020.2 The projected increase in
morbidity and mortality due to COPD is likely to
result in substantial increase in the burden of the
disease in terms of economic costs. For instance,
episodes of exacerbation of COPD, generally
associated with progression of the disease, are
responsible for many emergency hospital admis-
sions, which in the UK have risen by 50% in the last
5 years.3 In Italy, COPD is the respiratory disease
with the biggest number of hospital discharges, and
ranks 7th overall among all diseases.4,5
In Italy, it has been estimated that mean cost per
patient/year for patients diagnosed with COPD
between 1999 and 2000 ranged from 1500 to 3912
Euros, depending on illness severity.6 A study has
shown that exacerbations are the key drivers of the
costs of COPD in Sweden accounting for between 35
and 45% of the total per capita health-care costs for
COPD.7 A number of studies have found evidence
that inhaled corticosteroids (ICS) might have an
attenuating effect on airway hyper-responsiveness,
in addition to helping to reduce exacerbations
among moderate to severe COPD patients.8–11 The
recently produced ATS/ERS COPD treatment guide-
lines now recommend long-term use of ICS for COPD
patients with post-bronchodilator forced expira-
tory volume in 1 s (FEV1) o50% predicted and
repeated exacerbations and as many as 48% of
COPD patients in the UK are currently receiving
long-term ICS therapy.12,13 Evidence from a recent
clinical trial indicates a combined effect bet-
ween fluticasone propionate (an inhaled corticos-
teroid) and salmeterol (a long acting beta-agonist,
LABA) in reducing COPD exacerbations and other
clinical outcomes.14 Two recent observational
studies of combined inhaled corticosteroids and
LABAs, among moderate to severe COPD patients,
have reported reduced risk of mortality and re-
hospitalization.15,16 Both studies were based on
the UK General Practice Research Database (GPRD),
an automated database of primary care covering
a total population in excess of 3.4 million inhabi-
tants (approximately 5.7% of the population) in
the UK.The primary aim of the current study was to
explore whether the benefits achieved with com-
bining Short-acting beta agonists (SABA) and ICS are
similar to the observed beneficial effects of adding
a LABA to ICS in COPD patients. Therefore, using
the GPRD, we conducted a study to compare the
effectiveness of combination therapies involving
inhaled corticosteroids with either long-acting
beta-agonists or short-acting beta-agonists in re-
ducing the risk of re-hospitalization or death among
COPD patients within a year of discharge from a
first COPD hospitalization.Materials and methods
Database
All data were obtained from the GPRD. The GPRD
was originally developed in 1987 with the aim of
establishing a longitudinal database of medical
records in the UK. The database is managed by
the Medicines and Healthcare Products Regulatory
Agency (MHRA). It has been described else-
where,17–21 and has been used in other published
epidemiological studies on COPD.15,16,21,22 In line
with previous GPRD-based studies on COPD, we
identified retrospectively all male and female
newly physician-diagnosed COPD patients aged 50
years and older from 1990 to 1999. The study
protocol was approved by the Scientific and Ethical
Advisory Group of the GPRD.
Study cohort
The cohort was similar to those used in two
previously published retrospective studies; one
based on the Ontario database10 and the other on
the GPRD16 (Fig. 1). As in the previous GPRD-based
study, the cohort was restricted to newly diagnosed
COPD patients in the GPRD and cohort entry defined
at date of discharge from a first hospitalization for
a COPD-related condition. In addition, cohort
members were required to have received at least
one prescription for inhaled corticosteroids and at
least another prescription for either LABAs or SABAs
from their general practices (GPs) in the first 90
days after discharge. No restrictions were placed
on the use of other respiratory drugs and the
criteria for hospitalization for a COPD-related
condition included codes for pneumonia and chest
infection. However, patients with no record of GP
contact within any 12-month period were ex-
cluded. To ensure equitable definition of drug
exposure, an immortal person time-period of
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Figure 1 Study design: patients with events in the first 90 days following discharge from hospital are excluded.
Inhaled corticosteroids in COPD patients 111790-days was effected, such that patients who died
or were re-hospitalized or lost to follow-up within
90 days of discharge from hospital were ex-
cluded.23–25Drug exposure and outcome
Every patient in the study received at least one
prescription of ICS in the 90-day period following
the patient’s discharge from first COPD-related
hospitalization. Over the same period, those who
also received at least one prescription of a LABA
constituted the ICS plus LABA group, whilst the
others who received at least one prescription of
SABAs made up the ICS plus SABA group. Thus,
patients who were given prescriptions of both
LABAs and SABAs over the said period were assigned
to the ICS plus LABA group. The outcome of interest
was the occurrence of a first severe COPD exacer-
bation, defined here as either re-hospitalization for
a COPD-related medical condition or death. Follow-
up was restricted to a maximum period of 365 days
from discharge date. The choice of 365 days was to
ensure consistency with other previously published
studies on the subject matter, and to command
sufficient power to analyze the research hypothesis
as well as to maintain completeness of the
database.Study design
We used a propensity scores-matched cohort de-
sign. The propensity scores were derived from the
patient-level baseline characteristics on asthma
status, smoking, age, comorbidities, prior respira-
tory medications and gender. We then matched
users of ICS plus LABA to users of ICS plus SABA withequal probabilities of being prescribed ICS plus
LABA.
In a randomized trial, the randomization of
subjects to different treatment groups guarantees
that, on average, there should be no systematic
differences (i.e. bias) between treatment groups.
In observational studies however, investigators do
not assign the treatment as in a randomized trial.
Therefore, large differences in observed covariates
in the two treatment groups may exist, and these
differences could lead to biased estimates of
treatment effects. The propensity score is the
conditional probability of assignment to a particu-
lar treatment given a set of observed covariates
and is increasingly being used to adjust for non-
random treatment assignment.26–28Statistical analysis
Baseline characteristics of the two drug exposure
groups (i.e. ICS plus LABA versus ICS plus SABA)
were compared using standard univariate statisti-
cal techniques. For age at first COPD-related
hospitalization, being a continuous variable, we
compared the mean and standard deviation for the
groups using Fisher’s exact method. For the binary
and ordinal variables, w2 tests were performed.
Using standard survival techniques such as
Kaplan–Meier estimation and the Cox proportional
hazards model, we compared the event rates
between the two treatment groups. For this
purpose, duration of follow-up was defined as the
time-period between discharge from first COPD-
related hospitalization and either the next COPD-
related hospitalization, death or censoring (i.e. end
of record on database and hence considered lost to
follow-up). A number of baseline characteristics
(including age at first COPD-related hospitalization)
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adjusted hazard ratios (as relative risks).
Confounders
Asthma: A reasonable number (more than 40%) of
COPD patients in the GPRD have asthma mentioned
in their record. Indeed there is evidence that
compared with non-asthmatics, asthma patients
have 17-times-higher risk of receiving a diagnosis of
emphysema and as much as 12.5-times-higher risk
of fulfilling COPD diagnostic criteria regardless of
smoking history.29Table 1 Descriptive characteristics of COPD patients wi
the first 90 days of discharge from a first COPD-related ho
scores (with 90-day event-free restriction).
Before matching
ICS & SABA I
Total 2112 A
N
W
Mean age (SD) 71.6 (9.0) 6
Percent
Male 50.6
Current smoker 54.9
Asthma recorded previously 69.1
Baseline respiratory drug use in the 90 days prior to first
Inhaled steroids 100.0 1
Inhaled B2 100.0 1
Oral B2 4.6
Xanthynes 17.3
Anticholinergics 22.5
Oral steroids 35.8
Non-ICS combination products 2.9
Oxygen 7.7
Nebulized 2.5
Nasal corticosteroids 4.2
Antihistamines 2.4
Baseline comorbidity
Myocardial infarction 9.9
Congestive heart failure 25.4
Peripheral vascular disease 2.7
Cerebrovascular disease 3.8
Dementia 0.9
Rheumatologic disease 1.1
Peptic ulcer 7.1
Mild liver disease 0.0
Diabetes 5.2
Diabetes with complication 0.0
Hemiplegia or paraplegia 1.2
Renal disease 1.1
Cancer 0.8
Moderate/severe liver disease 0.2
AIDS 0.0
*Po0:05 in comparison between groups.Baseline medications: These were other respira-
tory medications used in the 90-day therapy
definition period and were treated as nine distinct
class variables (see Table 1). For instance, use of
oral corticosteroids being a potential effect modi-
fier of the association between therapy and
mortality was a binary yes/no covariate.30
Smoking: Information on tobacco use was cate-
gorized as either non-smoker (to represent never
and ex-smoker), current-smoker or unknown based
on patient’s records in both the medical and
prevention databases.th ICS and LABA versus those with ICS and SABA within
spitalization before and after matching by propensity
After matching
CS & LABA ICS & SABA ICS & LABA
ll 445 437 All 437
o SABA 102 No SABA 101
ith SABA 343 With SABA 336
8.5 (8.3)* 69.1 (8.6) 68.5 (8.3)
49.4 49.7 49.4
54.4 59.0 55.2
85.2 85.8 84.9
COPD-related hospitalization
00.0 100.0 100.0
00.0 100.0 100.0
5.2 3.4 5.3
23.6* 20.6 23.6
30.3* 28.4 30.0
52.6* 51.7 51.7
5.2* 3.4 5.3
8.8 8.2 8.9
5.2* 3.4 5.0
3.2 4.8 3.0
2.7 3.0 2.7
8.3 7.8 8.5
17.8* 17.2 17.8
2.9 2.3 5.3*
2.7 3.0 2.7
0.2 0.2 0.2
1.3 1.1 0.9
9.7 7.1 9.6
0.0 0.0 0.0
7.2 5.9 7.1
0.0 0.0 0.0
0.2 0.9 0.2
1.3 1.1 1.4
0.4 0.5 0.5
0.9* 0.2 0.7
0.0 0.0 0.0
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from patients’ medical records prior to the end of
the therapy definition window and were based on
the 15 Charlson comorbidity groups.31
Year of entry: The year of entry into the drug
exposure category was considered as a continuous
covariate in the analysis with the first year as 0.Results
We identified 2557 patients, each with records of a
first COPD-related hospitalization, followed by at
least one prescription of ICS and at least another
for either LABAs or SABAs or both in the first 90 days
of discharge (Table 1). The ICS plus LABA group was
comprised of 445 patients, with 343 (77%) having
also had prescriptions for SABAs in the 90-day
treatment definition period. As per treatment
group inclusion criteria, none of the 2112 patients
who constituted the ICS plus SABA group received
any prescription for (LABA) in the 90-day treatment
definition period. The proportions of patients with
prescriptions for the various other respiratory
medications were general higher in the ICS plus
LABA group, possibly indicating difference in the
severity of COPD between the two groups. How-
ever, the resulting propensity scores-matched pairs
of patients, 437 in each group were balanced on the
various variables, except on co-existing peripheral
vascular disease. The groups were also balanced on
quarterly oral corticosteroids prescriptions they
indicated a pattern of gradual reduction over theTable 2 Mean (SD) prescriptions of inhaled corticoste
agonists, and oral corticosteroids by drug exposure group,
1st Quarter 2nd Qua
Number
ICS & SABA 437 437
ICS & LABA 437 437
ICS
ICS & SABA 2.40 (1.34) 1.83 (1.5
ICS & LABA 2.54 (1.45) 2.08 (1.5
LABA
ICS & SABA 0.00 (0.00) 0.07 (0.3
ICS & LABA 2.36 (1.25)* 2.02 (1.5
SABA
ICS & SABA 3.41 (2.19) 2.75 (2.3
ICS & LABA 2.62 (2.40)* 2.23 (2.2
OCS
ICS & SABA 1.15 (1.47) 0.79 (1.3
ICS & LABA 1.16 (1.62) 0.93 (1.5
*Po0:05 in comparison between groups.year since discharge from the COPD-related hospi-
talization (Table 2).
Survival
Over the 1-year follow-up period, re-hospitaliza-
tion or death occurred in 132 patients (15.1%)
overall, 12.1% among users of ICS plus LABA
(regardless of use of SABA) compared with 18.1%
among those who used ICS plus SABA (and no LABA)
(Po0:05). Re-hospitalization occurred in 6.4% of
the users of ICS plus LABA compared with 10.1%
among users of ICS plus SABA. Similarly, death
occurred in 6.9% of the users of ICS plus LABA
compared with 9.6% among the users of ICS plus
SABA.
The results from a Cox survival analysis with
adjustments for possible confounders showed that
use of ICS plus LABA was associated with 38% fewer
events of re-hospitalization or death compared to
ICS plus SABA use (relative risk ¼ 0.62, 95%
confidence interval 0.43–0.87). The survival func-
tions for the two treatment groups are presented in
Fig. 2. Estimates for the other risk factors for re-
hospitalization or death are shown in Fig. 3 and
include sex, age, comorbid conditions (including
asthma), and use of oral corticosteroids.
Since almost 70% of the patients in the ICS plus
LABA group also received prescriptions for SABA in
the 90-day treatment definition period, a stratified
Cox analysis was also conducted. The results
revealed a risk reduction of 49% among those who
used ICS plus LABA and no SABA (relativeroids, long-acting beta-agonists, short-acting beta-
per quarter in the propensity scores-matched cohort.
rter 3rd Quarter 4th Quarter
437 437
437 437
3) 1.60 (1.55) 1.42 (1.65)
3)* 1.80 (1.58) 1.54 (1.52)
9) 0.11 (0.54) 0.08 (0.42)
3)* 1.66 (1.49)* 1.40 (1.53)*
3) 2.54 (2.39) 2.18 (2.49)
1)* 1.96 (2.10)* 1.68 (2.11)*
3) 0.77 (1.29) 0.68 (1.20)
8) 0.86 (1.54) 0.70 (1.45)
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V. A. Kiri et al.1120risk ¼ 0.51, 95% confidence interval 0.26–0.99),
and a risk reduction of 35% among those who used
ICS plus LABA and some SABA (relative risk ¼ 0.65,
95% confidence interval 0.44–0.94) relative to
those given only ICS and SABA.
When re-hospitalization only was considered as
the outcome of interest, we found similar evidence
of risk reductions in favour of use of ICS plus LABA
over use of ICS plus SABA. Figure 4 gives the results
from a Cox survival analysis involving adjustments
for possible confounders. They showed that use of
ICS plus LABA was associated with 42% fewer events
of re-hospitalization than use of ICS plus SABA
(relative risk ¼ 0.58, 95% confidence interval
0.36–0.95). Furthermore, when death was consid-
ered as the outcome of interest, we also found0
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Figure 2 Adjusted Cox survival function of time to re-
hospitalization or death in COPD patients using inhaled
corticosteroids (ICS) with either long-acting beta-ago-
nists (LABA) or short-acting beta-agonists (SABA).similar evidence of risk reductions in favour of use
of ICS plus LABA over use of ICS plus SABA. Figure 5
gives the results from a Cox survival analysis
involving adjustments for possible confounders.
They showed that use of ICS plus LABA was
associated with 40% fewer deaths than use of ICS
plus SABA (relative risk ¼ 0.60, 95% confidence
interval 0.37–0.98).Discussion
In this study we found that prescriptions of ICS plus
LABA versus ICS plus SABA, in the 90 days following
discharge for a COPD-related hospitalization, sig-
nificantly reduced the risk of re-hospitalization or
death by as much as 38% (13–57%) for COPD
patients in the 12 months following discharge from
hospital after adjusting for potential confounding
variables. A bigger level of risk reduction was
observed among those given ICS plus LABA in the
absence of SABA, when compared with those given
ICS plus SABA only.
When the risk of re-hospitalization alone and
death alone were separately assessed, we also
found evidence of reduced risk within a year of
discharge among those who were given ICS and
LABA with or without SABA compared with those
who were given ICS and SABA without LABA.
The magnitude of the reported risk reductions
may have a large impact on the overall burden of
the disease in terms of public health, especially in
light of the estimation by Murray and Lopez that
COPD is expected to become the third leading
cause of death worldwide in 2020.32 Thus, evidence
of a better medication regimen capable of reducing
COPD-related hospitalization could assist efforts tothma OCS Non ICS
Combined
product
Nebulized   ICS &
   LABA
(no SABA)
 ICS &
 LABA
& SABA
| Respiratory medications
ospitalization or death in COPD patients using inhaled
ABA) or short-acting beta-agonists (SABA) without LABA.
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Figure 4 Multivariate Cox survival analysis of time to re-hospitalization in COPD patients using inhaled corticosteroids
(ICS) with either long-acting beta-agonists (LABA) or short-acting beta-agonists (SABA) without LABA.
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Figure 5 Multivariate Cox survival analysis of time to death in COPD patients using inhaled corticosteroids (ICS) with
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Inhaled corticosteroids in COPD patients 1121reduce the burden of the disease in terms of costs
to payers.
This study is a replication of two other observa-
tional studies, both of which reported reductions in
the risk of re-hospitalization or death among COPD
patients prescribed therapy of ICS with or without
LABA.10,16 However by applying a 90-day immortal
time period on a propensity scores-matched cohort
using scores derived from a list of possible con-
founding variables, ours attempted to minimize bias
from two possible sources to which the previousstudies were susceptible, namely, selection and
waiting-time bias. Waiting-time bias can result in
studies where the time to initiation of treatment is
included in the follow-up analysis.24 Although a
number of studies have failed to show a significant
effect of ICS on annual decline in FEV1,
33a recent
systematic review of eight trials data has reported a
slowing of about 8ml/year in FEV1 decline with ICS
use.34 The effectiveness of ICS on health status and
in reducing the number or severity of exacerbations
has also been reported elsewhere.35,36
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GPRD-based study that combining LABA with ICS
enhances the benefit of ICS with or without SABA.
In our case, the observed beneficial association of
ICS plus LABA with reduction in the risk of re-
hospitalization is of high statistical and clinical
significance. To our knowledge this is the first study
that assesses the possible beneficial effect of
concomitant ICS and LABA compared with conco-
mitant ICS and SABA on re-hospitalization in COPD
patients treated in general practice.
ICS and LABAs have a well-established role in the
treatment of asthma.37 By contrast, the position in
COPD has been inconclusive. Nevertheless, the
findings of the present study support the evidence
of improved outcomes from combining ICS and
LABA in treating COPD as reported elsewhere in a
previous GPRD-based study 16as well as the evi-
dence of beneficial effect reported for ICS in COPD
treatment reported from a study of a different
healthcare system.10
One of the strengths of this study is the three-
fold approach to guarantee the reliability of
physician-diagnosed COPD. We first identified the
diagnosis from the computerized general practice
record in the GPRD using at least one of the terms
for COPD, which have already been reported as
valid in distinguishing COPD from asthma in the
GPRD.37 The diagnosis was then subsequently
confirmed by a hospital doctor on discharge from
hospital for a COPD-related admission and as
further safeguard only patients over 50 years old
were included in the study. Other demographic
features such as smoking history were supportive.
Indeed, the high mortality observed in our study
population would by itself make frequent misdiag-
nosis of asthma unlikely. A previous GPRD-based
study which used these procedures has reported
mortality rate among moderate to severe COPD
patients as between 114–398 per 1000 person-
years, compared with a mere 52 per 1000 person-
years among non-COPD patients of similar age.38
Thus, these procedures and statistics have helped
to establish the validity of the diagnosis of COPD in
this GPRD cohort.
The GPRD is one of the few sources for
investigating the implications of therapy on disease
management, using data from ‘real-life’ patients.
It is one of the largest population-based medical
databases in the world. For instance, it has an
advantage over health maintenance organization
databases in the USA where elderly people are
frequently lost to follow-up. To maintain the GPRD,
GPs from participating surgeries enter morbidity
events for each patient in the database using a
medical coding system (OXMIS20 and Read codes).This is irrespective of whether the event occurred
in the surgery, at a visit, or was relayed via
telephone. Symptoms, procedures, investigations,
diagnoses, prescriptions, referrals, and follow-ups
are all recorded. A similar database is managed by
the Italian Society of General Medicine (SIMG) and
recent publications have also resulted from the
database.39–42 Indeed, a study of the database,
involving the Italian Society of Respiratory Medi-
cine, is in progress to assess the effectiveness of ICS
plus LABA compared to ICS plus SABA in the
treatment of Italian COPD patients on similar
outcomes such as mortality and hospitalization.
The study will allow us to check in another
European country with a different climate, the
validity of the findings of the current study. It is
important to point out that the latter reflects the
implications of treating ‘real-life’ COPD patients
outside the rigorous randomized clinical trial
setting where patients are usually highly selected
and it is vital to ensure maintenance of the
medication regimes under scrutiny.
Nevertheless, compared with data from a rando-
mized clinical trial, the GPRD lacks valid, complete
information on important variables like respiratory
function, body weight, alcohol and tobacco con-
sumption. Differential diagnosis or drug dosages are
often difficult to assess. However, the major
diagnoses and information on use of health services
and medication are registered with a reasonable,
acceptable degree of validity.20 Indeed, the draw-
backs of the database are adequately offset by its
large sample size and extensive content in terms of
information on medical and therapy events, which
are available from practices in all parts of the UK.
The lack of randomization means that, as with
most similar observational studies, bias due to
confounding by indication was a potential weakness
of our study, namely that treatment for some
patients might have been chosen because of the
presence or absence of specific features of the
disease.43 We accept that such a bias was poten-
tially capable of reducing or enhancing the appar-
ent treatment effect since severity of the disease
or indeed other disease characteristics such as
comorbid asthma could affect both choice of
treatment and prognosis.
However, in our study, the restriction of the age
group to 50 years and older would make misdiag-
nosis of asthma as COPD unlikely, even after
allowing for the possibility of late onset of asthma.
Furthermore, the results were adjusted for comor-
bidities to minimize the impact of disease severity
and from the prescription records for the two
treatment groups and we could find nothing to
suggest that the patients in the ICS plus SABA group
ARTICLE IN PRESS
Inhaled corticosteroids in COPD patients 1123received less attention from their GPs. By matching
both treatment groups on certain relevant re-
corded baseline variables, we have also reduced
the possibility of selection bias. Indeed, based on
the oxygen and nebulized treatments received in
the unmatched full cohort, those given ICS plus
LABA might be more severely ill than those
prescribed ICS and SABA without LABA.44
The present study has confirmed improved out-
comes with the combination therapy of ICS with
LABA relative to ICS with SABA, in terms of reduced
risks of re-hospitalization or death or both within
12 months among users with moderate to severe
COPD treated in the UK general practice setting. If
confirmed in randomized controlled trials, the
beneficial associations reported in this observa-
tional study would clearly bring health benefits to
COPD patients, which in turn should mean reduc-
tions in both the costs of management of the
disease as well as its overall burden on the society.Acknowledgements
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